Screening Strategies for Rare Disease Targets

Rare disease screening occupies a uniquely challenging position in pharmaceutical research, where the standard tools of large-scale drug discovery must be adapted to the realities of poorly characterized targets, scarce patient-derived biological material, and clinical trial populations that may number in the hundreds or fewer. An estimated 7,000–10,000 rare diseases have been identified globally, yet fewer than 5% have an approved treatment, leaving more than 300 million people worldwide without effective therapeutic options.¹

The passage of orphan drug legislation — beginning with the US Orphan Drug Act in 1983 and followed by equivalent frameworks in the European Union, Japan, and Australia — has substantially increased pharmaceutical investment in rare disease drug discovery. Yet the structural challenges of screening for orphan disease targets persist: biological models are difficult to generate and validate, patient cohorts are too small for standard biomarker stratification, and the mechanistic basis of many rare conditions remains incompletely understood. These factors demand screening strategies that differ markedly from those used in more prevalent therapeutic areas.²

The challenge of screening for orphan disease targets

The fundamental difficulty of rare disease drug discovery is that the tools and assumptions underlying conventional high-throughput screening are calibrated to diseases with well-characterized biology, abundant patient samples, and defined molecular targets. Many rare diseases — particularly those with ultra-rare prevalence (fewer than one in 100,000 individuals) — lack validated target structures, established biochemical assay formats, and the genetic model organisms needed to test compound efficacy in vivo. The result is a discovery landscape where standard target-based screening, even when applied, frequently yields hits that do not translate to disease-relevant contexts.

A further constraint is the limited availability of patient-derived biological material. Primary cells from patients with rare metabolic, lysosomal, or neurodegenerative disorders are difficult to obtain in sufficient quantities for large-scale screening campaigns, and immortalized cell lines often lack the disease-specific phenotypes needed to generate meaningful pharmacological data. These limitations have driven a transition towards phenotypic screening approaches that prioritize the observation of disease-relevant cellular endpoints in the most biologically authentic models available, even when throughput is necessarily lower than in cell-line-based assays.³

Phenotypic screening with patient-derived cells

Phenotypic screening using primary cells derived directly from patients with a rare disease has emerged as a preferred strategy in a growing number of inherited metabolic and lysosomal storage disorder programs. Rather than beginning from a molecular target hypothesis, this approach defines a measurable cellular phenotype — such as abnormal substrate accumulation, impaired lysosomal function, disrupted mitochondrial membrane potential, or deficient protein trafficking — and uses this readout to identify compounds that restore normal cellular behavior. The approach does not require prior knowledge of the precise molecular mechanism, making it applicable even when target identity is uncertain or multiple pathogenic pathways converge.³

Patient cell-based phenotypic assays are most tractable for cell-autonomous disorders in which the disease phenotype is faithfully recapitulated in isolated cells, including fibroblasts, lymphoblasts, or peripheral blood mononuclear cells obtained from affected individuals. The key advantage over heterologous cell systems is biological authenticity: patient cells carry the native genetic context, including the full complement of modifier alleles and epigenetic marks that influence drug response, providing a pharmacological readout that is directly relevant to the target population. Throughput is inherently constrained by the availability of primary cells, making compound library prioritization through computational pre-filtering an important upstream step in these workflows.

Table 1. Comparison of screening strategies applicable to rare disease drug discovery programs.

Induced pluripotent stem cell models for rare disease drug screening

The development of induced pluripotent stem cell (iPSC) technology has significantly expanded the toolkit available for rare disease screening by providing a renewable, patient-specific source of disease-affected cells that can be differentiated into the relevant tissue type. Patient-derived iPSCs reprogramd from somatic cells — typically skin fibroblasts or peripheral blood mononuclear cells — retain the complete genetic architecture of the donor, including the causative mutation and any modifying variants, and can be differentiated into neurons, cardiomyocytes, hepatocytes, or other cell types relevant to the pathology under investigation.⁴

iPSC-derived disease models have been applied to phenotypic drug screening in a range of rare conditions including lysosomal storage disorders, rare neurological diseases such as the neuronal ceroid lipofuscinoses, and metabolic disorders of the liver. The ability to generate defined quantities of a consistent cell type from a single patient-derived line addresses the supply limitations of primary cell screening, while isogenic CRISPR-corrected controls — in which the disease-causing mutation is precisely reverted — provide an internal comparator that substantially reduces the confounding effects of genetic background variation.⁵

Practical limitations of iPSC-based screening include the time and cost required to establish, validate, and differentiate iPSC lines, the variable efficiency of differentiation protocols across different patient genotypes, and the maturation state of derived cells, which may not fully recapitulate the functional properties of adult tissue. Standardization of differentiation protocols, quality control criteria, and phenotypic endpoint selection remains an active area of work in the field.

Drug repurposing as a rapid-entry strategy for orphan disease targets

Drug repurposing — identifying new therapeutic applications for compounds already approved for other indications — has become one of the most widely used strategies in rare disease drug discovery, offering a route to clinical evaluation that bypasses the extensive safety characterization required for novel chemical entities. Because the safety and pharmacokinetic profiles of approved drugs are already established, repurposed candidates can in principle progress from preclinical identification to Phase II clinical evaluation substantially faster than de novo compounds, a critical advantage in small patient populations where clinical trial recruitment is slow and resource-intensive.³

Computational approaches to drug repurposing have become increasingly central to rare disease programs. Network-based methods that map approved drugs onto molecular interaction networks constructed from genomic, transcriptomic, and proteomic data can identify drugs with mechanistic plausibility for a given orphan disease, even when direct experimental data are absent. Knowledge graph frameworks — which integrate gene-disease associations, protein-protein interactions, and drug-target relationships into a unified analytical structure — have demonstrated the ability to surface repurposing hypotheses for rare conditions with limited published literature, including Duchenne muscular dystrophy, Friedreich's ataxia, and rare lysosomal storage diseases.⁶

Key applications of repurposing-focused screening in rare disease include:

• Transcriptomic signature matching: identifying approved drugs whose gene expression signatures are inversely correlated with the disease transcriptome, suggesting potential reversal of pathological gene expression patterns
• Phenome-wide association study (PheWAS) analysis: mining electronic health record data to identify drugs associated with reduced disease burden in patients who receive them for other indications
• Patient registry-linked pharmacovigilance: systematic analysis of adverse event databases and registry data to identify protective drug effects in rare disease patient populations
• High-content phenotypic screening of approved drug libraries: direct experimental screening of repurposing sets (typically 1,000–3,000 compounds) in patient-derived cell models at manageable throughput

Artificial intelligence and precision medicine approaches in rare disease screening

The application of artificial intelligence (AI) and machine learning to rare disease drug discovery has expanded rapidly, driven by the recognition that the data poverty characteristic of ultra-rare conditions can be partially offset by the integrative analytical power of modern computational methods. AI platforms trained on large-scale biomedical datasets — including genomic databases, clinical trial records, electronic health records, and published literature — can generate and rank drug repurposing hypotheses for rare diseases that have too few patients to support conventional drug development programs.⁷

Accelerate your PROTACs drug discovery and development

This eBook shows how an integrated, end-to-end analytical approach helps labs generate reliable, regulatory-ready PROTAC data at every stage of development.
View eBook

Advertisement

Natural language processing applied to the biomedical literature is increasingly used to extract pharmacological relationships from publications, case reports, and patent filings relating to rare diseases, enabling the systematic construction of disease-specific knowledge graphs that would be impractical to assemble manually. Deep learning models applied to high-content imaging data from patient-derived cell screens can extract phenotypic features invisible to conventional image analysis, identifying subtle morphological signatures of drug activity that correspond to mechanistically interpretable cellular changes.⁶

Precision medicine approaches are also reshaping the clinical translation of rare disease screening hits. Because rare diseases are often genetically heterogeneous — with different mutations in the same gene producing distinct pathophysiological subtypes — screening strategies are increasingly designed to identify mutation-specific therapeutic responses, rather than assuming a uniform treatment effect across all patients with the same diagnosis. Biomarker-stratified screening designs that incorporate genotype-phenotype correlation data from patient registries enable more efficient allocation of limited experimental resources to the patient subpopulations most likely to respond to a given compound.⁸

Outlook for rare disease screening and orphan drug development

The trajectory of rare disease screening is towards greater integration of patient-derived biological models, computational data mining, and genotype-aware clinical trial design. The establishment of international rare disease patient registries, biobanks of well-characterized patient cell lines, and standardized iPSC differentiation protocols is creating a shared infrastructure that allows screening resources to be pooled across academic, biotech, and charitable research organizations — a critical development given the limited patient populations and research funding available for individual rare conditions.

Regulatory frameworks are adapting in parallel, with agencies including the FDA and EMA developing guidance for the use of single-arm trials, adaptive designs, and natural history control arms in rare disease development programs. As the scientific and regulatory environment continues to evolve, the gap between the identification of a rare disease target and the availability of an approved therapy is beginning to narrow — though for the majority of the estimated 7,000–10,000 rare diseases still without treatment, the challenge of building and executing effective screening programs remains substantial.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.